Patent application number | Description | Published |
20080220409 | Antigen of Dengue Virus Type 1 - Antigens and B-cell epitopes derived from dengue virus type 1 are provided. The antigens are specifically immunoreactive with sera from individuals infected with dengue virus type 1 but not reactive with sera from healthy individuals and individuals infected with dengue virus type 2. The antigens and epitopes are useful for development of diagnostic kits and reagents, and are useful tools as well in determining whether an individual is infected with dengue virus type 1, and for distinguishing infection from dengue virus type 2. | 09-11-2008 |
20090054363 | Genetic markers and methods for detecting and treating cancers - The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and/or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue. Furthermore, the identified genetic marker SOX5 and/or SPARC can also be used for cancer targeted therapy, because down regulation of SOX5 and/or up regulation of SPARC expression in NOD-SCID can retard tumor growth and inhibit cell proliferation, migration, invasion and metastasis. | 02-26-2009 |
20100119444 | Tumor-Targeting Peptides and Uses Thereof - Tumor targeting peptides and uses thereof in tumor diagnosis and treatment. | 05-13-2010 |
20110275105 | Methods of inducing pluripotency - Methods are provided for inducing non-pluripotent cells to become pluripotent. Methods also include identifying and isolating induced pluripotent (iPS) cells and uses thereof. Compositions and kits for carrying out the subject methods are also provided. | 11-10-2011 |
20120014945 | Anti-Dengue Virus Antibodies - Provided herein are monoclonal antibodies specific to dengue virus as well as their antigen-binding fragments, and functional variants. Also disclosed are uses thereof for treating or diagnosing dengue virus infection. | 01-19-2012 |
20120039988 | CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER THERAPY - Cancer-targeting peptides and uses thereof in cancer therapy. | 02-16-2012 |
20120093721 | USES OF CANCER-TARGETING PEPTIDES IN CANCER DIAGNOSIS - Cancer-targeting peptides and uses thereof in cancer diagnosis. | 04-19-2012 |
20130084298 | NOVEL ANTI-CLATHRIN HEAVY CHAIN MONOCLONAL ANTIBODY FOR INHIBITION OF TUMOR ANGIOGENESIS AND GROWTH AND APPLICATION THEREOF - A purified monoclonal antibody, or an. antigen-binding portion thereof, which specifically binds to human clathrin heavy chain (CHC) is disclosed. The antibody, or antigen-binding portion, thereof, exhibits at least one, two, three, four, five, six, seven, or all eight of the following properties: (a) specifically binds to pancreatic adenocarcinoma cells; (b) binding to the cell surface and cytosol of cancer cells and tumor blood vessels; (c) internalized by CHC-expressing cells; (d) inhibiting tumor growth, invasion ability, migration, and angiogenesis; (e) inducing apoptosis in cancer cells and human umbilical vein endothelial cells; (f) inhibiting tumor growth and tumor blood vessels in pancreatic cancer in vivo; (g) suppressing epidermal growth factor, transferrin, and VEGF internalizations by cancer cells; and (h) suppressing hypoxia-inducible factor-1α expression and vascular endothelial growth factor secretion. Methods for inhibiting tumor cell growth and/or angiogenesis, and detecting cancer in a subject is also disclosed. | 04-04-2013 |
20130115170 | GM1-LIKE PEPTIDES AND USES THEREOF - Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases. | 05-09-2013 |
20130209365 | Anti-C-Met Antibody and Methods of Use Thereof - Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc. | 08-15-2013 |
20140112935 | ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF - The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer. | 04-24-2014 |
20150017230 | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF - An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed. | 01-15-2015 |